Long-term Follow-up of Subjects Treated With CAR T Cells
Recruiting
Observational Study
Long Term Adverse Effects
CAR-T
Duty to Follow Up
Adult
Progression-Free Survival
Disease-Free Survival
Overall Survival
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 45 (estimated)
- Sponsor
- Marcela V. Maus, M.D.,Ph.D. · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit.
Subjects meeting the following criteria are eligible for study participation:
* Provision of voluntary written informed consent by subject
* CAR T cells were administered in DF/…
Contacts